

MINUTES OF FINANCIAL EVALUATION COMMITTEE MEETING FOR PRICE JUSTIFICATION FOR TENDER NO.- BMSIC/DRUGS/24-12/RE-TENDER (RE-TENDER FOR RATE CONTRACT AND SUPPLY OF QUADRIVALENT HUMAN PAPILLOMA VIRUS (SEROTYPES 6, 11, 16 & 18) VACCINE (RECOMBINANT) (QHPV) FOR DIFFERENT HEALTHCARE FACILITIES OF STATE OF BIHAR).

Date: 03rd January 2025

Venue: BMSICL Conference Hall.

The Financial Evaluation Committee Meeting for price justification for Tender No. BMSIC/DRUGS/24-12/RE-TENDER was held on 03rd January 2025 under the Chairmanship of Managing Director, BMSICL. The other committee members present in the meeting were:

1. Director in Chief, Health Department, GoB.
2. Smt. Kumari Seema, CGM (Supply Chain), BMSICL.
3. Sh. Harendra Ram, GM (Procurement), BMSICL.
4. Sh. Rajesh Kumar, Administrative Officer-cum-I/C Procurement, SHSB.
5. Sh. Gautam Kumar, Asst. Internal Financial Advisor (IFA), of Health Department, GoB.
6. Dr. Vidyapati Choudhary, Principal PMCH, Patna.
7. Sh. Ramendra Kumar, GM (Finance), BMSICL.

2. The Details of the invited tender are as follows:

1. Tender Reference No. BMSIC/DRUGS/24-12/RE-TENDER.
2. Tender floated date- 26/11/2024.
3. Last date of submission of online bids- 11/12/2024.

3. The Tender has been floated on e-proc2 Portal for the Drug Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) (0.5 ml - 1 dose) Injection.

4. Total two (02) bidders were found to have successfully submitted their bids on the e-proc2 online system. The submission status of original hard copy of Earnest Money Deposit (EMD), till the stipulated time was found as following: -

S. N.	Name of the Firm	Online submission status of bids on E-Proc2	Requisite Amount of EMD receipt Status	Remarks
1	M/s MSD Pharmaceuticals Private Limited	Ok	Received	Ok
2	M/s Serum Institute of India Private Limited	Ok	Received	Ok

5. The item wise bid received status was as follows:

S.N.	Name of the Drug	Participating Firms	No. of Bids
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited	2
		M/s Serum Institute Of India Private Limited	

6. It was therefore unanimously decided by TEC to recommend for evaluating the both received bids.

7. After evaluating the bids and close examination of the documents submitted by the firms, the Drug wise technical evaluation findings for each firm were recorded in its meeting dated 13.12.2024 with the help of Drugs Inspectors deputed at BMSICL as follows:

S.N.	Name of the Drug	Participating firms	Technical Qualification Status (Qualified/ Disqualified)	Remarks
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s MSD Pharmaceuticals Private Limited	Qualified	Ok
		M/s Serum Institute of India Private Limited	Qualified	Ok

8. According to the comparative chart above, a total of two (02) bidders namely, M/s MSD Pharmaceuticals Private Limited & M/s Serum Institute Of India Private Limited were found technically qualified.

9. It was therefore unanimously decided by TEC in its meeting dated 13.12.2024 to recommend for opening of the financial bids of the technically qualified bidders on e-proc2 portal.

10. Accordingly, the financial bids of technically qualified bidders were opened on 16.12.2024 on e-proc2 portal, in which the following result has been observed: -

S. N.	Name of the Drug	Participating firms	Quoted Rate (Rs.) for Each Unit (Excluding GST)	Quoted Rate (Rs.) for Each Unit (Including GST@5%)	Bid Ranking
1	Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV)	M/s Serum Institute of India Private Limited	866.67	910	L1
		M/s MSD Pharmaceuticals Private Limited	1495	1569.75	L2

11. As per the comparative chart, the L1 rate is Rs. 910/- (Including GST @ 5%) per Vial for the product Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) quoted by the firm M/s Serum Institute of India Private Limited. It was unanimously decided by Financial Evaluation Committee in its meeting dated 16.12.2024 to ask the L1 bidder for justify their quoted price for the above said product.

12. Accordingly, the meeting was held today. The firm M/s Serum Institute of India Private Limited reduced the rate for the product Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV). The new L1 rate for the product Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) is **Rs. 856/- (Excluding GST) i.e, Rs. 898.8/- (Including GST @ 5%)**. Hence it was unanimously decided to recommend for issue the Letter of Intent to M/s Serum Institute of India Private Limited for the product Quadrivalent Human Papilloma Virus (Serotypes 6, 11, 16 & 18) Vaccine (Recombinant) (qHPV) at L1 rate i.e, **Rs. 898.8/- (Including GST @ 5%)**.

13. The meeting thus concluded with a vote of thanks.

Sd/-
(Ramendra Kumar)
GM (Finance), BMSICL, Patna.

Sd/-
(Dr. Vidyapati Choudhary)
Principal PMCH, Patna.

Sd/-
(Gautam Kumar)
Asst. Internal Financial Advisor, Health Dept.,
Govt. of Bihar.

Sd/-
(Rajesh Kumar)
Administrative Officer-cum-I/C Procurement,
SHSB.

Sd/-
(Harendra Ram)
GM (Procurement), BMSICL, Patna.

Sd/-
(Kumari Seema)
CGM (Supply Chain), BMSICL, Patna.

Sd/-
Director in Chief, Health Dept., Govt. of Bihar.

Sd/-
(Dharmendra Kumar)
Managing Director, BMSICL.